Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Corrado Cilio

Professor

Default user image.

S100A9 in inflammation

Author

  • Zhifei He

Summary, in English

S100A9 is a small (13 kD) cytosolic calcium-binding protein. The protein is mainly expressed in neutrophils and monocytes in human but can also be expressed in other cell types under inflammatory conditions. S100A9 is normally co-expressed with S100A8 and forms S100A8/S100A9 heterodimers. Previous publications had suggested that S100A9 could be expressed without S100A8 in certain conditions. Various functions for cytosolic S100A8/S100A9 heterodimers have been described. The heterodimer can promote NADPH oxidase activation, is involved in reactions mediated by the iNOS enzyme and assists in tubulin polymerization. Extracellular S100A9 can bind to TLR4 and RAGE. Upon binding TLR4, S100A9 functions as a DAMP molecule inducing a pro-inflammatory cellular response. This thesis mainly focuses on the pro-inflammatory function of hS100A9.

In paper I, the main questions we asked were: in what condition hS100A9 could exist in cells without hS100A8? We found that the half-life of hS100A9 protein was short and degraded fast in cells, but can be stabilized by co-expressing with hS100A8 or by proteasome inhibitor. We also found that inflammatory stimuli could also stabilized hS100A9 protein and promoted the formation of proteolytically-resistant homodimer. This paper suggests that during inflammatory condition, hS100A9 protein might be able to exist as homodimer without hS100A8 and that it therefore may function as DAMP molecule after it has been released out of the cell.

In paper II, we showed that a chemical probe oxyclozanide could inhibit S100A9, S100A4 and S100A4/S100A9 binding to TLR4 and RAGE and inhibiting tumor progression in a mouse model. We also showed that hS100A4 and hS100A9 can form heterodimers. Further, we showed that S100A4 and S100A9 are differentially expressed in mouse myeloid cell populations.

In paper III, we wanted to identify co-receptor(s) involved in S100A9-mediated stimulation of TLR4. We show that CD14 is an essential co-receptor of this stimulation. Our data also suggest that some other co-receptor(s) might exist that help in S100A9 binding to cell membrane. However CD14 was crucial both for S100A9 signaling and internalization.

In summary, in this thesis we discuss the relation between S100A9 and inflammation. We show that during inflammation, the pro-inflammatory cytokine could stabilize the unstable hS100A9 by promoting it forming proteolytically-resistant homodimer. After S100A9 released out of the cell, they could function as DAMP molecule activating TLR4 in a CD14 dependent way. By blocking the interaction between the S100s with their receptors using OX, we propose a compound with clinical potential for treating inflammation and cancer.

Department/s

  • Immunology

Publishing year

2016

Language

English

Document type

Dissertation

Publisher

Lund University: Faculty of Medicine

Topic

  • Immunology in the medical area

Keywords

  • S100A9
  • inflammation
  • oxyclozanide
  • CD14

Status

Published

Research group

  • Immunology

Supervisor

  • Fredrik Ivars
  • Corrado Cilio
  • Tomas Leanderson

ISBN/ISSN/Other

  • ISBN: 978-91-7619-315-0

Defence date

23 September 2016

Defence time

13:00

Defence place

Segerfalksalen, BMC A10, Sölvegatan 17, Lund.

Opponent

  • Nancy Hogg (professor)